VENUS REMEDIES LTD. - 526953 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Compliance under reg 39(3) for stop transfer.29-06-2024
29-06-2024
VENUS REMEDIES LTD. - 526953 - Venus Remedies Clinches WHO-Backed PAHO Tender, Takes Its Global Fight Against Cancer To Next Level
Venus Remedies Clinches WHO-backed PAHO Tender.20-06-2024
Venus Remedies up 8% on order win from UNICEF for bacterial infection drug
The uptick in stock price came after the company announced that it has secured an award for its antibiotic product, Ceftriaxone 1 gm, from UNICEF13-06-2024
VENUS REMEDIES LTD. - 526953 - Venus Remedies Achieves Major Milestone With UNICEF
Venus Remedies achieves major milestone with UNICEF by securing the prestigious tender for its antibiotic product.13-06-2024
VENUS REMEDIES LTD. - 526953 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper publication of financial results as on 31st March 202401-06-2024
VENUS REMEDIES LTD. - 526953 - Financial Results As On 31.03.2024.
Financial results as on 31.03.202430-05-2024
VENUS REMEDIES LTD. - 526953 - Board Meeting Outcome for Outcome Of Board Meeting Dated 30.05.2024
1. Audited Financial Results for the quarter and year ended on 31st March 2024 along with Audit report. 2. Amended the Code of conduct to regulate, monitor and reporting of trading by designated persons/insiders and Code of practices and procedures for fair disclosure of unpublished price sensitive information, both are available on Company website-www.venusremedies.com.30-05-2024
VENUS REMEDIES LTD. - 526953 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Stop Transfer intimation.22-05-2024
VENUS REMEDIES LTD. - 526953 - Board Meeting Intimation for Board Meeting Scheduled To Be Held On 30Th May 2024.
VENUS REMEDIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2024 ,inter alia, to consider and approve 1. Audited Standalone and Consolidated Financial Results for the quarter and year ended on 31st March 2024. 2. Any other business with the permission of Chair.18-05-2024